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Brief Communicationsthymoma), and 10% to 15% of patients with MG are found to have
a thymoma.1 An autoimmune mechanism dependant on CD4 T
lymphocytes is suspected to be responsible for the GCM, and
immunosuppressive therapy has been used to delay transplanta-
tion.3 Median survival or time to heart transplantation of 5 to 6
months had been reported in GCM.3 Ventricular assistance as a
bridge to heart transplantation was reported in patients who had
terminal heart failure within a week.4 Our patient, like the one
reported by Glennon and colleagues,2 presented in shock within
hours after the onset of symptoms, despite maximal medical treat-
ment. Both patients had no sign of active myocarditis before the
thymoma resection, and the operation might have in some way
triggered the disease. This very aggressive form of the disease after
a thymoma resection did not allow a premortem diagnosis and thus
the administration of appropriate immunotherapy or a ventricular
support device as a bridge to heart transplantation.3,4 Transplan-
tation remains the treatment of choice in the absence of recovery
of myocardial function with immunosuppressive agents, although
the disease is known to recur in the transplanted heart.3 Marelli andYung-Chie Lee, MD, PhD, Taipei, Taiwan
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The Journal of Thoraciwith biventricular assistance for 10 days and immunosuppressive
therapy with a follow-up of 3 years. Even if GCM appears to be a
very rare disease, this diagnosis should be considered in patients
who experience rapidly progressive heart failure after thymoma
resection. Although the possibility of massive pulmonary embo-
lism or myocardial infarction should not be ignored, early myo-
cardial biopsy might lead to the diagnosis. Appropriate immuno-
suppressive therapy and circulatory support as a bridge to
transplantation can be administrated.
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Using Surgicel to buttress the staple line in lung
volume reduction surgery for chronic obstructive
pulmonary disease
Jang-Ming Lee, MD, PhD, Jen-Deh Pan, MD, Wei-Cheng Lin, MD, andDr W. LeeAlthough effective for palliating the symptoms ofchronic obstructive pulmonary disease (COPD), lungvolume reduction surgery for COPD is highly vulner-able to postoperative major or persistent air leakage.1
Staple line reinforcement has been developed to prevent this
complication, including using polyglycolic acid,2 bovine pericar-
dial strips,3 or autologous parietal pleura.4 These materials either
carry a high cost2,3 or take a substantial amount of time for
preparation.4 A low-cost and easily available material for staple
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Copyright © 2006 by The American Association for Thoracic Surgerybuttressing is needed to facilitate its clinical application. We report
a new technique using oxidized regenerated cellulose (Surgicel,
Johnson & Johnson) for lung volume reduction surgery for COPD.
Clinical Summary
Patient 1. A 72-year-old man with COPD complained of
progressive exertional dyspnea unresponsive to bronchodilator
treatment. He had left pneumothorax and received a thoracoscopic
wedge resection on the pulmonary left upper lobe 4 years ago.
Chest computed tomography revealed diffuse emphysematous
change of the bilateral lung, especially in the right middle lobe. For
intractable dyspnea, video-assisted thoracic surgery for lung vol-
ume reduction surgery on the right lung was arranged. About 30%
of the pulmonary right upper lobe at the apex and 50% of the right
middle lobe at the basal portion was resected with a continuous
staple line (Figure 1, B, C, and D). Before the lung resection, a
strip of Surgicel, 4  8 cm, was tied on each site of the staple
(Figure 1, A). The working port on the anterior axillary line of the
fourth intercostal space was enlarged to 3 cm to prevent disloca-
tion of fixed Surgicel during staple introduction. A total of 7 sets
of Endo-GIA, 60  4.8 mm, and 2 sets of Endo-GIA, 45  4.8
mm, staples (Tyco Health Care, US Surgical) were used during the
operation. It took 2 hours for the e
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Brief Communicationspatient was extubated the day after the operation, with no air
leakage found from the chest tube. The chest tube was removed 3
days later, and the patient was discharged 7 days after the
operation.
Patient 2. A 56-year-old man with bullous emphysema had
exertional dyspnea for 10 years. He had an episode of right tension
pneumothorax before admission. He underwent endotracheal intu-
bation and right chest tube thoracostomy in our emergency depart-
ment for pneumothorax-induced respiratory failure. Chest com-
puted tomography disclosed diffuse pulmonary emphysema with
multiple small- to median-sized bullae in the bilateral lungs, es-
pecially in the right middle and lower lobes, and 2 huge bullae of
13 cm in diameter in the right lower lobe. Lung volume reduction
surgery with bullectomy was suggested after he was weaned from
a ventilator. During the operation, a thoracotomy through the
seventh intercostal space was created for precise excision of the
Figure 1. A, Surgicel tied on each site of the staple. B, Lung
specimens, 15  4 and 5  3 cm, were excised from the right
upper lobe and right middle lobe, respectively. C, Lung surface
after resection (before saline pleural irrigation). D, Lung surface
after resection (after saline pleural irrigation).multiple lesions. Part of the pulmonary right upper and lower lobes
496 The Journal of Thoracic and Cardiovascular Surgery ● Febrwith the most evident bullous formations was resected with 5 and
2 sets of GIA 90  4.8–mm and 50  4.8–mm staples (Tyco
Health Care, US Surgical), respectively. Before staple application,
one strip of Surgicel was tied on each side of the staple to buttress
the staple line, as previously described. The surgical procedure
took 2 hours and 30 minutes in total. The patient was extubated on
the day of the operation. Minimal air leakage was noted from the
chest tube after the operation, and the tube was removed 6 days
after the operation, the same day as patient discharge.
Discussion
The oxidized cellulose compound Surgicel is currently indicated
for hemostasis during surgical intervention. In pigs Surgicel cov-
erage with local electroablation can significantly decrease air leak-
age from pleural tears.5 Our preliminary experience demonstrated
that using Surgicel to buttress the staple line can effectively
prevent postoperative air leakage after lung volume reduction
surgery either in open or thoracoscopic procedures. Only a few
minutes are required to attach it to the staple. The fixed Surgicel
did not interfere with the staple application during lung resection.
However, to avoid dislocation of the Surgicel fixed in the staple,
we suggest a slight enlargement to the working port for staple
application during the video-assisted thoracic surgery procedure.
In contrast to other expensive buttress materials, Surgicel is com-
monly used in the operating theater, with a cost less than 5% of the
bovine pericardium used in this country. Further studies examining
efficacy and safety are necessary.
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